METHOD FOR PREDICTING CLINICAL COURSE OF DYSPLASTIC AND NEOPLASTIC PROCESSES IN CERVIX UTERI

The method for predicting the clinical course of dysplastic and neoplastic processes in cervix uteri comprises the sampling of the biological materials, the preparation of the histological sections, the pathohistological and immunohystochemical examination of the specimens, the assay of the expression of the tumor suppression genes, the detection of papilloma virus, the assessment of dysplasia or the neoplastic alterations of the tissue of cervixuteri based on the data on increasing or decreasing of the expression of the tumor suppression genes followed by the assessment of the probability of progression or generalization of cancer defining the appropriate indications for the complex treatment. In addition, Ki-67 monoclonal is used for detecting proliferation marker. p53 expression is assessed as the key regulator of apoptosis and the controller of the genome integrity. VEGF is assessed as the growth factor of vascular endothelium; bcl-2 is assessed as apoptosis blocker, and pl6INK4A is assessed as the inhibitor of cyclin-dependent kinases and the indicator of the malignization of the cells of cervical epithelium. DNA of highly oncogenic types of papilloma virus is searched for using DNA probe techniques. The properties of the cells in the specimens are assessed by the analysis of p53, bcl-2, and the staining with Ki-67 monoclonal. The presence of the dysplastic process is assessed by the analysis of pl6INK4A. Finally, high orlow oncogenic risk is defined and favorable or unfavorable course of the process is predicted.